Postbiotic delivery system for oral microbiome modulation
Innovative platform utilizing bacterial extracellular vesicles for targeted oral microbiome modulation, enhancing beneficial species and reducing inflammation. Compatible with toothpaste and mouthwash, offering sustained or pH responsive release for daily use.
Overview
BioClé's postbiotic delivery system leverages bacterial extracellular vesicles (bEVs) to modulate the oral microbiome precisely. This innovative platform targets microbial communities in the oral cavity to promote beneficial species and reduce dysbiotic signaling, thereby lowering gingival inflammation. Unlike broad spectrum antimicrobials, bEVs offer targeted modulation without disrupting overall microbial balance. This system is designed for integration into everyday oral care products like toothpaste and mouthwash, providing options for sustained or pH-responsive release for effective daily use.
Technical specifications
Key features:
- Utilizes nanoscale bEVs for targeted delivery of bioactive compounds and microbial metabolites
- Promotes health-associated microbial communities without disrupting overall balance
- Compatible with existing oral care products (toothpaste, mouthwash)
- Engineered for sustained or pH-responsive release
- Non-living, cell-free postbiotics that fit within current regulatory frameworks
The platform is scalable and flexible, allowing easy formulation into various oral care products while maintaining stability and compatibility with standard excipients like fluoride and surfactants. It supports rapid iteration across different active compounds and formats.
Technology readiness level
The technology is currently at TRL 4, having validated efficacy in oral-relevant models. Future validation plans include scale-up optimization, safety studies, and pilot product integration. BioClé is open to co-development, licensing, supply partnerships, and equity investments, with potential for exclusivity in certain applications.
About BioClé
BioClé is a biotechnology startup that has developed an intelligent delivery platform based on bacterial extracellular vesicles (bEVs). The technology is designed to enhance the stability, bioavailability, and targeted cellular uptake of bioactive compounds, which often lose efficacy due to degradation during digestion. By utilizing modified bacteria to produce these vesicles at scale, the company aims to solve significant challenges in the delivery of ingredients such as butyrate, allowing them to reach intestinal cells intact and active. The company employs synthetic biology and biological nanotechnology to create a delivery system that functions as a natural vehicle for health and nutritional applications.
Operating with a B2B business model, BioClé intends to partner with laboratories, nutraceutical companies, and food manufacturers by providing them with a technology platform to improve the performance of their functional products. By addressing the limitations of traditional delivery methods like capsules or liposomes, the company seeks to enable next-generation gut health solutions. Based in Rosario, Argentina, with an international outlook, BioClé was incubated at the Institute of Molecular and Cellular Biology of Rosario (IBR) and is supported by investment firms including GRIDX. The company is actively validating its platform through both in vitro and in vivo studies to support commercial adoption.
Inquire about this partnering listing
Looking for
Industry applications
delivered to your inbox.